Valuation: Vectura Group

Market Cap 100.46Cr 88Cr 81Cr 76Cr 142.54Cr 9.48TCr 145.5Cr 975.87Cr 377.61Cr 4.68TCr 377.23Cr 368.99Cr 16TCr P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 93Cr 82Cr 75Cr 70Cr 131.98Cr 8.77TCr 134.72Cr 903.6Cr 349.64Cr 4.34TCr 349.29Cr 341.66Cr 15TCr EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
31/25/31 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
17/24/17 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
16/24/16 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
29/21/29 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
03/21/03 Philip Morris CEO does not need M&A to hit smoke free goals RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 01/06/2016
Corporate Secretary - 30/06/2025
Director TitleAgeSince
Director/Board Member 53 15/09/2023
Director/Board Member 57 30/06/2025

Financials

2019 2020
Net sales 18Cr 16Cr 14Cr 13Cr 25Cr 1.68TCr 26Cr 173.2Cr 67Cr 831.26Cr 67Cr 65Cr 2.88TCr 19Cr 17Cr 15Cr 14Cr 27Cr 1.8TCr 28Cr 185.15Cr 72Cr 888.6Cr 72Cr 70Cr 3.08TCr
Net income -2.21Cr -1.94Cr -1.79Cr -1.67Cr -3.14Cr -208.47Cr -3.2Cr -21Cr -8.31Cr -103.03Cr -8.3Cr -8.12Cr -357.27Cr 12Cr 11Cr 9.89Cr 9.26Cr 17Cr 1.15TCr 18Cr 118.9Cr 46Cr 570.65Cr 46Cr 45Cr 1.98TCr
Net Debt -6.65Cr -5.83Cr -5.37Cr -5.03Cr -9.44Cr -627.31Cr -9.63Cr -65Cr -25Cr -310.03Cr -25Cr -24Cr -1.08TCr -7.44Cr -6.52Cr -6.01Cr -5.63Cr -11Cr -701.83Cr -11Cr -72Cr -28Cr -346.86Cr -28Cr -27Cr -1.2TCr
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-